Mailankody, Sham http://orcid.org/0000-0002-2815-9561
Matous, Jeffrey V.
Chhabra, Saurabh http://orcid.org/0000-0001-9117-8696
Liedtke, Michaela
Sidana, Surbhi http://orcid.org/0000-0003-3288-7614
Oluwole, Olalekan O.
Malik, Shahbaz
Nath, Rajneesh
Anwer, Faiz
Cruz, Jose Carlos
Htut, Myo
Karski, Erin E.
Lovelace, Wade
Dillon, Myles
Butz, Eric
Ying, Wendy
Balakumaran, Arun
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Article History
Received: 1 July 2022
Accepted: 12 December 2022
First Online: 23 January 2023
Change Date: 17 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-023-02306-7
Competing interests
: S.M. received consulting fees from Evicore, Optum, BioAscend, Janssen Oncology and Legend Biotech. Memorial Sloan Kettering Cancer Center receives research funding from the NCI, Janssen Oncology, Bristol Myers Squibb, Allogene Therapeutics, Fate Therapeutics and Takeda Oncology for conducting research. S.M. received honoraria from OncLive, Physician Education Resource, MJH Life Sciences and Plexus Communications. C.S. received institutional research funding from Janssen, Bristol Myers Squibb, Amgen, Novartis, Syndax, Ionis, Allogene and Sanofi GSK and honoraria for advisory boards/speakers bureau from Sanofi, GSK and Omeros. J.V.F., S.A.M., J.C.C. and M.H. report no competing interests. L.M. received honoraria from Pfizer and clinical trial funding from Caelum. L.M. is a member of the Board of Directors or other advisory committees at Alnylam, Bristol Myers Squibb, Caelum, Celgene, GlaxoSmithKline, Janssen Pharmaceuticals, Karyopharm, Kite, Kura Oncology, Oncopeptides, Pfizer, Sanofi and Takeda. S.S. reports consultancy fees from Janssen, Magenta Therapeutics and Bristol Myers Squibb, as well as research funding from Magenta Therapeutics and Allogene. O.O.O. held consultancy and advisory board roles for Pfizer, Kite, Gilead, AbbVie, Janssen, TGR therapeutics, Novartis, curio science and Nekktar, and received institutional funding from Kite, Pfizer, Daichi Sankyo and Allogene and honoraria from Pfizer and Gilead. R.N. reports consultancy fees and honoraria from Actinium and Incyte. F.A. received personal fees from Bristol Myers Squibb as a speaker and a fee from Janssen pharmaceutical as an advisory board member. F.A. consulted or held an advisory role for Seattle Genetics, Incyte Corporation Speakers’ Bureau and Company: Incyte Corporation and received travel and accommodation expenses from Seattle Genetics and Incyte and honoraria from Incyte. Without receiving direct funding, F.A. served as the local principal investigator for Allogene Therapeutics, Celgene, GlaxoSmithKline, Bristol Myers Squibb, Seattle Genetics, Acetylon Pharmaceuticals, Millennium, Astellas Pharma and AbbVie. E.E.K., W.L., M.D. and A.B. are employees of Allogene Therapeutics. E.B. and W.Y. are consultants with Allogene Therapeutics who do not own stock. S.K.K. receives institutional funding for clinical trials from Abbvie, Amgen, Allogene, AstraZeneca, Bristol Myers Squibb, Carsgen, GlaxoSmithKline, Janssen, Novartis, Roche-Genentech, Takeda, Regeneron and Molecular Templates. S.K.K. also participated in consulting/advisory boards without personal payment for Abbvie, Amgen, Bristol Myers Squibb, Janssen, Roche-Genentech, Takeda, AstraZeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium, Loxo Oncology, K36, Sanofi and ArcellX, and with personal payment for Oncopeptides, Beigene, Antengene and GLH Pharma.